Hexedrone
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Hexedrone (2-(methylamino)-1-phenylhexan-1-one) is a synthetic stimulant of the cathinone class. It is the N-methyl homolog of N-ethylhexedrone, differing by a single carbon on the amine nitrogen. Hexedrone is a norepinephrine-dopamine reuptake inhibitor, producing its effects by blocking dopamine and norepinephrine clearance from the synapse.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamines, cocaine, cathinones +1 moreamphetamines, cocaine, cathinones, dopaminergic stimulants show less
First reported to the EMCDDA Early Warning System by Poland in July 2013,[3] hexedrone was structurally confirmed from seized samples by Błażewicz et al. in 2017.[4] Its N-ethyl structural analog N-ethylhexedrone achieved far broader market distribution, becoming one of the most frequently seized stimulant designer drugs in Europe.[5] Hexedrone itself remains a minor presence on novel psychoactive substance markets, overshadowed by its more prevalent relative.
Subjective effects include euphoria, focus enhancement, thought acceleration, and a pronounced compulsive redosing urge.[6] The experience is narrowly stimulant — a focused, dopamine-driven push without the empathogenic warmth of mixed-mechanism cathinones like mephedrone. Cardiovascular strain, anxiety, and a dysphoric comedown are characteristic unsought effects.
Dependence liability is moderate to high, driven by potent DAT blockade, and fatal intoxications from the closely related N-ethylhexedrone have occurred at blood concentrations not far above those seen in non-fatal cases.[5][7] The compulsive redosing pattern typical of DAT-selective stimulants encourages binge use, which compounds cardiovascular and psychiatric risk with each successive dose.[8] No controlled study has been published for hexedrone itself — the current understanding rests entirely on analog inference from N-ethylhexedrone and user reports.[6]
History[edit]
Discovery
Hexedrone's structural class traces to pharmaceutical patents filed by Boehringer Ingelheim in the 1960s, where compounds in the MDPV development lineage were first described.citation needed The compound attracted no clinical or recreational attention for decades until July 2013, when Poland reported a seized sample to the EMCDDA Early Warning System — the first documented appearance of hexedrone as a novel psychoactive substance.[3] Formal structural confirmation came four years later, when Błażewicz et al. identified hexedrone alongside three other novel cathinones from Polish seizures using NMR and mass spectrometry.[4]
Market trajectory
Hexedrone was rapidly eclipsed by its N-ethyl structural analog, N-ethylhexedrone (NEH), which appeared on European markets in late 2015 and was reported by five countries within three months.[3] By 2017 NEH had become the most frequently seized stimulant designer drug in Hungary.[5] This asymmetry shaped the published literature — virtually all pharmacological and clinical data concern NEH rather than hexedrone itself.
Regulatory response
NEH was temporarily placed in US Schedule I in May 2019 and permanently scheduled on June 1, 2022.[9] Internationally, NEH was added to the UN Convention on Psychotropic Substances Schedule II in March 2020.[10] Hexedrone itself has not been individually scheduled at the UN or US federal level, though generic cathinone controls in several countries capture it.
The name follows the systematic cathinone naming convention: "hex-" for the six-carbon backbone, "-edrone" from cathinone. It sits in a homologous series — buphedrone (C4), pentedrone (C5), hexedrone (C6), heptedrone (C7) — each named for its chain length. The compound never acquired street names or a distinct subcultural identity, remaining a catalog entry rather than a recognized substance among stimulant users.
Chemistry[edit]
Structural class
Hexedrone is a substituted cathinone — a β-keto amphetamine — within the phenethylamine superfamily. Its parent scaffold is cathinone, the naturally occurring stimulant alkaloid of Catha edulis (khat). The molecule extends this scaffold with an N-methyl group on the amine nitrogen and a butyl chain at the α-carbon, giving the backbone a six-carbon span.
Hexedrone sits in the homologous N-methyl cathinone series: buphedrone (C4) → pentedrone (C5) → hexedrone (C6) → heptedrone (C7). Replacing the N-methyl with N-ethyl yields N-ethylhexedrone, the more widely studied member of this structural pair. The β-keto group is the defining feature separating cathinones from amphetamines — it reduces blood-brain barrier penetration relative to the corresponding amphetamine analogs.
Molecular properties
| Molecular formula | C₁₃H₁₉NO |
| Molecular weight | 205.30 g/mol |
Values confirmed via PubChem.[11] The molecule comprises a phenyl ring bonded to a carbonyl (ketone) group, a secondary amine bearing a methyl group, and a four-carbon aliphatic chain. Hexedrone is typically encountered as a white crystalline powder in seized samples. No published data on melting point, solubility, or stability have been identified.
Stereochemistry
Hexedrone possesses a single chirality center at C2. The (S)-enantiomer is predicted to be the more pharmacologically active isomer at monoamine transporters, based on enantioselectivity patterns established across the cathinone class.[12] No enantiospecific data have been published for hexedrone itself, and commercial samples are presumed racemic mixture.
Pharmacology[edit]
Mechanism of action
Hexedrone functions as a norepinephrine-dopamine reuptake inhibitor (NDRI) — it blocks the DAT (DAT) and NET (NET) without inducing monoamine release. This classification is established for the closely related N-ethylhexedrone (NEH), which produces no monoamine efflux at DAT, NET, or SERT in human transporter-expressing cells.[1] Hexedrone, differing only by one carbon on the amine nitrogen, is expected to share this mechanism.
Hexedrone is sometimes misclassified as a monoamine releasing agent. Published transporter data for N-ethylhexedrone show no releasing activity at any monoamine transporter.[1] The compound acts solely through reuptake inhibitor.
The compound's high selectivity for DAT over SERT places it in the same pharmacological category as cocaine rather than mixed-mechanism cathinones like mephedrone or MDMA. This selectivity predicts a predominantly dopaminergic experience — stimulation, euphoria, and reinforcement — with minimal serotonergic effects such as empathogenesis or perceptual alteration.
Pharmacokinetics
No human pharmacokinetic data exist for hexedrone. All parameters below are inferred from N-ethylhexedrone studies and are explicitly flagged as structural analog inferences.
In a controlled study of intranasal NEH administration, the compound was detectable in oral fluid within the first hour, and approximately 0.2% of the dose appeared in sweat over four hours.[13] Clinical cases of NEH intoxication yielded the first elimination estimates: a plasma half-life of 19–28 hours, with urine detection persisting up to 10 days.[8]
The long elimination half-life contrasts sharply with hexedrone's short subjective duration (1–4 hours oral). This discrepancy — common among stimulant cathinones — reflects the difference between the peak effect window (driven by CNS concentrations) and the slower process of distribution and hepatic clearance. Whether hexedrone's N-methyl substitution meaningfully alters elimination kinetics relative to NEH is unknown.
Neuroscience[edit]
Where it acts
As a potent DAT inhibitor, hexedrone increases dopamine concentrations primarily in the nucleus accumbens — the core reward structure of the mesolimbic pathway. This mechanism underlies the euphoria and reinforcement common to all DAT-preferring stimulants. The high DAT/SERT selectivity ratio[1] means dopaminergic reward signaling dominates the acute experience, with minimal serotonergic modulation of mood or perception.
Norepinephrine reuptake inhibitor at NET[1] enhances prefrontal cortical function at low-to-moderate doses — sharpening focused attention and working memory. At higher doses, excessive catecholamine signaling impairs prefrontal function through an inverted-U dose-response, contributing to the decision impairment and compulsive redosing patterns characteristic of cathinone stimulant use.
Why it matters
The incentive salience model is directly relevant to hexedrone's pharmacology. DAT-selective stimulants preferentially enhance wanting (motivational drive to seek the drug) over liking (hedonic pleasure), because mesolimbic dopamine encodes incentive salience rather than hedonic value. This explains the pronounced compulsive redosing urge — the dopaminergic signal intensifies the drive to re-administer, often disproportionate to the actual pleasure achieved.
The post-intoxication syndrome documented in NEH cases — depression, irritability, anhedonia, psychomotor slowing[8] — reflects temporary dopamine depletion following sustained reuptake inhibition. Prolonged DAT blockade depletes vesicular dopamine stores and triggers compensatory receptor changes, producing a rebound effect low-dopamine state during recovery.
No neuroimaging or electrophysiology data exist for hexedrone or N-ethylhexedrone. Key unknowns include whether hexedrone causes dopaminergic neurotoxicity at recreational doses — in laboratory tests, the N-ethyl cathinone series shows greater cell toxicity than methamphetamine.[14] The relationship between dose and dopamine transporter occupancy in the living brain is entirely uncharacterized, and whether hexedrone's high DAT selectivity confers a specific psychosis vulnerability profile distinct from mixed-mechanism stimulants remains untested.
Subjective Effects[edit]
Hexedrone delivers a focused, narrowly stimulant experience shaped by its dopamine-dominant mechanism. At lower doses, the effect profile resembles functional stimulation — heightened alertness, concentration, and a sense of purposeful energy. As dose increases, euphoria intensifies but so does the compulsive compulsive redosing urge, which users consistently describe as disproportionate to the actual pleasure of the high. Set, setting, and prior stimulant tolerance modulate intensity substantially; stimulant-naive individuals report stronger cardiovascular and psychological effects at equivalent doses.
Hexedrone sits closest to pentedrone in the cathinone homologous series and shares cocaine's pharmacological mechanism — pure DAT/NET reuptake inhibitor — without cocaine's broader receptor activity. Compared to mixed-mechanism cathinones such as mephedrone, the experience is narrower: more purely stimulant, less empathogenic, and with a sharper drop into dysphoric comedown.
Effect Grid
Clear stimulant effects dominate: euphoria, enhanced focus, thought acceleration, and increased sociability form the core experience. Analysis enhancement and motivation enhancement are noticeable. Music enhancement and immersion enhancement may be present. Disinhibition and ego inflation emerge at this tier.
Physical effects become apparent — appetite suppression, vasoconstriction, and bruxism are common. Heart rate and blood pressure are elevated. Excessive sweating and dehydration sensation may occur. Spontaneous body sensations are possible.
The compulsive redosing urge becomes a defining feature at common doses. The short total duration (1–4 hours) combined with this urge creates significant binge risk. Aftereffects — including irritability, low mood, and cognitive fatigue — may persist 1–12 hours. Sleep is impossible for several hours after the last dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity enhancement · Tinnitus
Pupil dilation · Dry mouth · Insomnia · Physical fatigue · Body high · Excessive sweating · Heart rate perception changes · Muscle tension · Restlessness · Dehydration sensation · Nausea · Bodily lightness · Bruxism · Headache · Nasal congestion · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Trembling · Dizziness · Tingling / electric sensations · Motor control enhancement · Involuntary body movements · Vibrations / buzzing · Tactile hallucination
Body high · Excessive sweating · Heart rate perception changes · Muscle tension · Restlessness · Dehydration sensation · Nausea · Bodily lightness · Bruxism · Headache · Nasal congestion · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Trembling · Dizziness · Tingling / electric sensations · Motor control enhancement · Involuntary body movements · Vibrations / buzzing · Tactile hallucination
Focus enhancement · Motivation enhancement · Motivation suppression · Information processing enhancement · Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Immersion enhancement · Language enhancement · Memory enhancement · Thought organization · Aesthetic enhancement · Cognitive impairment · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Confusion · Thought disorganization · Thought loops
Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Immersion enhancement · Language enhancement · Memory enhancement · Thought organization · Aesthetic enhancement · Cognitive impairment · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Confusion · Thought disorganization · Thought loops
Irritability · Dysphoria · Emotional lability · Mania
Communication enhancement · Sociability enhancement · Social connection · Flow state
Timeline
Initial alertness and subtle mood shift emerge. A faint increase in heart rate may be noticed as the compound begins to take effect.
Rapidly building stimulation with euphoria emerging. Focus sharpens and sociability increases as dopaminergic effects intensify.
Full dopaminergic stimulation — euphoria, focus enhancement, thought acceleration, and appetite suppression are at maximum intensity. The compulsive redosing urge is strongest here. Cardiovascular effects (tachycardia, vasoconstriction) are most pronounced.
Effects diminish gradually. Motivation to redose persists even as euphoria fades. Irritability and restlessness may emerge as the stimulant state recedes.
Post-acute dysphoria phase — cognitive fatigue, low mood, anhedonia, and motivation suppression predominate. Appetite returns. Sleep may remain difficult for several hours.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamines · cocaine · cathinones
Toxicity
Acute toxicity
No controlled toxicity studies have been conducted for hexedrone. No lethal dose has been established for hexedrone or N-ethylhexedrone (NEH) in any species. All acute toxicity data derive from NEH case reports.safety citation needed
Two fatal NEH intoxications have been published. A 23-year-old with pre-existing heart disease died after consuming NEH alongside a synthetic cannabinoid, with postmortem blood NEH at 285 ng/mL.[5] A 21-year-old with no known pre-existing conditions developed body temperature exceeding 41 °C, heart rate above 160 bpm, and acute kidney failure, dying within hours at a postmortem blood concentration of 145 ng/mL.[7]
Non-fatal severe toxicity has also been documented: three patients required hospitalization 12–24 hours after intranasal NEH use, two of whom needed mechanical ventilation. One patient developed syndrome of inappropriate antidiuretic hormone secretion.[8] The gap between non-fatal blood levels (up to ~97 ng/mL) and fatal concentrations (145–285 ng/mL) suggests a limited safety margin.[5][8]
Heart and circulation
Hexedrone-class compounds produce a sympathomimetic toxidrome: rapid heart rate, elevated blood pressure, vasoconstriction, and dangerous overheating.[15] Pre-existing heart conditions — arrhythmia, cardiomyopathy, atherosclerosis — substantially increase the risk of fatal outcome.[5]
Cell toxicity
In laboratory tests, the N-ethyl cathinone series (including NEH) is more toxic to nerve-like cells than methamphetamine, with toxicity increasing as the carbon chain lengthens.[14] No in vivo neurotoxicity assessment has been published for hexedrone or NEH.
Psychological risks
Chronic cathinone use is associated with acute psychosis, paranoid thinking, and delusions — a psychiatric risk profile comparable to amphetamine-type stimulants.[16] Hexedrone's high DAT selectivity confers significant psychosis risk with heavy or binge-pattern use, as sustained dopaminergic overstimulation in reward pathways is the established driver of stimulant-induced psychosis.
Post-intoxication psychiatric symptoms documented in NEH cases include anxiety, feelings of persecution, anhedonia, and psychomotor slowing.[8] These symptoms may persist for days following heavy use. No data exist on hexedrone's potential to trigger lasting psychiatric conditions in vulnerable individuals.
Tolerance and dependence
Tolerance to hexedrone's stimulant effects develops with repeated use.[6] Community estimates place tolerance half-life at 3–7 days and full reset at 1–2 weeks.[6] Cross-tolerance occurs with other dopaminergic stimulants — amphetamines, cocaine, and other cathinones.
Dependence liability is moderate to high, driven by potent DAT inhibition. Psychological dependence is the primary concern; the compulsive redosing pattern characteristic of this class often escalates into binge use. Physical dependence is moderate.inferred
No formal withdrawal characterization exists. Expected withdrawal follows a dopaminergic rebound effect pattern: depression, irritability, cognitive fatigue, excessive sedation, and appetite enhancement.[8]
Drug interactions
No published drug interaction studies exist for hexedrone or N-ethylhexedrone. All risks below are class-level inferences.safety citation needed
MAO inhibitors pose the highest risk. Cathinone stimulants combined with MAOIs can cause dangerous blood pressure spikes through catecholamine accumulation. This combination is potentially fatal.
Other stimulants — amphetamines, cocaine, other cathinones, high-dose caffeine — produce additive cardiovascular strain: compounded rapid heart rate, elevated blood pressure, and overheating. Both published fatalities involved co-administered substances.[7][5]
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) may increase hexedrone blood levels if CYP2D6 is involved in its metabolism, as inferred from structural analog data,[17] potentially elevating toxicity risk.
Serotonergic agents (SSRIs, SNRIs, triptans) carry theoretical serotonin syndrome risk at high doses, though hexedrone's extreme DAT/SERT selectivity[1] makes this substantially lower-risk than with mixed-mechanism cathinones.
Blood pressure medications may be counteracted by hexedrone's sympathomimetic cardiovascular effects.
Contraindications
No contraindication data have been confirmed for hexedrone specifically. The following are class-level inferences.safety citation needed
Heart disease — including arrhythmia, cardiomyopathy, coronary artery disease, uncontrolled high blood pressure, and atherosclerosis — is an absolute contraindication. Pre-existing cardiac pathology was identified as a co-factor in a published fatal case.[5]
Concurrent MAOI use is an absolute contraindication.
Kidney impairment is a relative contraindication, given the acute kidney failure documented in one fatality.[7]
Seizure disorders warrant caution, as stimulant cathinones may lower seizure threshold.[5]
Psychiatric conditions — particularly psychotic disorders, bipolar disorder, and severe anxiety — are relative contraindications due to the risk of stimulant-induced psychosis.[16]
Pregnancy and breastfeeding are absolute contraindications due to unknown developmental risks and expected cardiovascular and thermal stress.safety citation needed
Harm Reduction[edit]
Forms & Identification
Hexedrone typically appears as a white crystalline powder, visually indistinguishable from dozens of other cathinone stimulants. Because hexedrone has minimal market presence compared to its N-ethyl structural analog (N-ethylhexedrone), mislabeling is a realistic concern — the Domagalska (2021) fatality involved powder initially misidentified as cocaine.[7]
Reagent testing can confirm the cathinone class but cannot reliably distinguish hexedrone from structurally similar cathinones. Quantitative analysis through drug checking services, where available, is the only way to verify both identity and purity. Given the narrow gap between recreational and dangerous blood concentrations, knowing exactly what and how much is in a sample is unusually important for this compound.
Guidelines
- Test every batch with reagent kits and, where possible, a drug checking service
- Weigh doses with a milligram-precision scale — do not estimate by eye
- Pre-portion a single session's worth and physically separate the remainder before dosing
- Stay hydrated but do not overhydrate — aim for moderate, steady fluid intake
- Eat a meal before use; cathinone stimulants suppress appetite during the session
- Set a firm cutoff time — the compulsive redosing urge is consistently reported as stronger than the actual high warrants
- Avoid physical exertion in warm environments; monitor body temperature if possible
- Do not use alone; inform someone of what was taken and when
Set & Setting
Hexedrone's short peak and intense redosing urge make environmental planning especially important. Using in a setting where additional doses are readily accessible increases the probability of binge use. Stimulant-naive individuals should expect stronger cardiovascular effects than experienced users at the same dose.
A trusted, sober companion can help monitor for escalating heart rate, overheating, or behavioral changes that the user may not recognize during the stimulant peak. Quiet, temperature-controlled environments reduce the risk of dangerous overheating — one of the documented causes of fatal outcome.[7]
Aftercare & integration. The post-stimulant comedown from hexedrone-class cathinones involves a predictable dopamine rebound effect: low mood, fatigue, irritability, and difficulty concentrating. These effects are temporary but can be distressing, especially after binge use.
Prioritize sleep — even if it feels unattainable immediately after the stimulant wears off. Eat nutrient-dense food, hydrate steadily, and avoid caffeine or other stimulants during the recovery window. Physical and emotional baseline typically returns within 1–3 days for single-session use; repeated or binge use extends recovery proportionally. If low mood, anhedonia, or paranoid thoughts persist beyond several days, seek professional support — these symptoms have been documented in clinical cases of N-ethylhexedrone intoxication.[8]
Recovery & Support
Hexedrone's compulsive redosing pattern and dopamine-driven reinforcement can establish habitual use that is difficult to interrupt without structured support. If use has become regular or binge-pattern, professional help improves outcomes.
Stimulant-specific resources include SAMHSA's National Helpline (1-800-662-4357, US), local addiction services, and peer support groups. Cognitive behavioral therapy has the strongest evidence base for stimulant use disorders. There is no pharmacological treatment specific to cathinone dependence, but structured support for the psychological dimensions of dependence is effective.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, body temperature hot enough to feel through clothing, extreme confusion or aggression, and breathing difficulty all require immediate help. An uncomfortable but safe stimulant experience involves anxiety and rapid heartbeat that stabilize; an emergency involves symptoms that escalate or do not resolve.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Move the person to a cool environment and remove excess clothing
- 3. If unconscious but breathing, place in the recovery position
- 4. Do not restrain unless there is immediate danger of self-harm
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (or "a synthetic cathinone stimulant" if unsure), the amount taken if known, the time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
Legal Status[edit]
Hexedrone occupies an ambiguous regulatory position: it has not been individually scheduled under most national or international frameworks, but falls within generic cathinone controls in several jurisdictions. Its N-ethyl structural analog, N-ethylhexedrone (NEH), has received specific scheduling at both national and international levels, reflecting NEH's greater market prevalence and associated harms.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not individually scheduled; Federal Analogue Act applies | Hexedrone is not listed in the DEA Controlled Substances schedules. It is subject to prosecution under the Federal Analogue Act (21 U.S.C. § 813) when intended for human consumption. N-ethylhexedrone was permanently placed in Schedule I on June 1, 2022.[9][18] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under the generic cathinone catch-all clause.[6] |
| Germany | Controlled (NpSG) | Controlled under the Neue-psychoaktive-Stoffe-Gesetz since November 26, 2016. Production and import with intent to market, administration to others, and trading are punishable. Possession is prohibited but not penalized.[6] |
| United Nations | Not individually scheduled | N-ethylhexedrone was added to the UN Convention on Psychotropic Substances Schedule II in March 2020.[10] Hexedrone was not included. |
| Canada | Likely controlled (class provision) | N-ethylhexedrone is Schedule I. Hexedrone's individual status is not confirmed; likely captured under cathinone class provisions.citation needed |
| Australia | Likely controlled (class provision) | Synthetic cathinones are broadly controlled under state/territory legislation and the Therapeutic Goods Act. Specific scheduling of hexedrone by name not confirmed.citation needed |
Analog liability
In jurisdictions with structural analog legislation — notably the US Federal Analogue Act — hexedrone's status depends on whether it is deemed "substantially similar" in structure and effect to a scheduled cathinone. Given its single-carbon difference from Schedule I N-ethylhexedrone, prosecution under analog provisions is considered probable but untested in case law for hexedrone specifically.
references
- [1]
- [2] ^Persson M, Vikingsson S, Kronstrand R, Green H (2024) Characterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method. — Drug Testing and Analysis doi:10.1002/dta.3547
- [3]
- [4] ^abBłażewicz A, Bednarek E, Sitkowski J, Popławska M, Stypułkowska K, Bocian W, Kozerski L (2017) Identification and structural characterization of four novel synthetic cathinones: α-methylaminohexanophenone (hexedrone, HEX), 4-bromoethcathinone (4-BEC), 4-chloro-α-pyrrolidinopropiophenone (4-Cl-PPP), and 4-bromo-α-pyrrolidinopentiophenone (4-Br-PVP) after their seizures — Forensic Toxicology doi:10.1007/s11419-017-0360-2
- [5]
- [6]